PIK3CA and colorectal carcinoma: Collectively, the co-occurrence of PIK3CA and KRAS has implications for targeted therapies, as treatments targeting PIK3CA-mutant CRC must also be effective against tumors harboring both PIK3CA and KRAS mutations to achieve optimal therapeutic outcomes.